Trials / Recruiting
RecruitingNCT06832410
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of VX-880 in Subjects With Type 1 Diabetes With a Kidney Transplant
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Biological/Vaccine | Infused into the hepatic portal vein. |
Timeline
- Start date
- 2025-03-31
- Primary completion
- 2026-09-17
- Completion
- 2027-09-17
- First posted
- 2025-02-18
- Last updated
- 2026-03-23
Locations
7 sites across 3 countries: United States, Canada, Saudi Arabia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06832410. Inclusion in this directory is not an endorsement.